Relapsed/Refractory Multiple Myeloma
Conditions
Brief summary
This study is a multicenter, observational, single-arm real world study. The purpose of this study is to describe demographic and disease characteristics, treatment patterns, and clinical outcomes in the real-world setting among participants in China with relapsed/refractory multiple myeloma (RRMM) who have been treated with Equecabtagene Autoleucel. This study will use both prospective and retrospective data
Detailed description
Primary endpoint: Best Overall Response Rate (BOR): The proportion of patients who receive treatment with Ikeolensay injection and have been evaluated by researchers as having the best disease status is strict complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR). Secondary endpoint: Progress Free Survival (PFS) rate at 6 months: The probability of patients not experiencing disease progression or death from any cause after receiving treatment with Ikeolensay injection for 6 months; Overall survival (OS) rate at 6 months: the probability of survival of patients after receiving treatment with Ikeolensay injection for 6 months; Time to Response (TTR): The time interval between the patient receiving treatment with Ikeolensay injection and the first recorded time of disease remission; Time to Complete Response (TTCR): The time interval between the patient receiving treatment with Ikeolensay injection and the first recording of complete disease response (CR or sCR); Adverse Event (AE): After receiving treatment with Ikeolensay Injection, researchers consider all adverse events and serious adverse events (SAE) related to Ikeolensay Injection treatment; Hospitalization: After receiving treatment with Ikeolensay injection, the researcher considers any hospitalization related to Ikeolensay injection treatment (including the reason, duration, and outcome of hospitalization); Death: The death of the patient after receiving treatment with Ikeolensay injection, recording the date and cause of death (any reason); Secondary malignant tumors: For any secondary malignant tumors discovered during the monitoring process, researchers can obtain tumor biopsy samples and other necessary samples of tumor tissue according to clinical needs, relevant guiding principles, and product instructions for safety analysis; Quality of life: Evaluate the quality of life using the EQ-5D and EORTCQLQ C30 scoring standards; Medical resource utilization: Collect any medical resource utilization information related to the treatment of patients with Ikeolensay injection (including hospitalization, emergency, outpatient, and new prescription drug usage).
Interventions
DRUGEquecabtagene Autoleucel
Equecabtagene Autoleucel (CT103A) is a novel fully human BCMA-targeting CAR-T therapy
Sponsors
Peking University People's Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patients with confirmed relapsed/refractory multiple myeloma; * Based on clinical practice, the physician decided to administer equecabtagene autoleucel treatment; * Voluntarily sign the informed consent form approved by the ethics committee.
Exclusion criteria
* Patients who are hypersensitive to the active ingredients of the product or any excipients (dimethyl sulfoxide, compound electrolyte injection, human albumin); * The researcher believes that patients are unable to return for follow-up visits or that it is impossible to complete the study; * Patients with expected survival less than 3 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Best Overall Response Rate， BOR | up to 24 weeks | Patients treatmented with Equecabtagene Autoleucel, the optimal disease state evaluated by the researcher is strict complete response (sCR),complete response (CR), very good partial response (Very Good Partial Response (VGPR) or partial response (partial response,PR) rate. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PFS rate of 6 month | up to 24 weeks | Probability of patients not experiencing disease progression or death from any cause 6 months after starting treatment with equecabtagene autoleucel |
| OS rate of 6 month | up to 24 weeks | Probability of patient survival 6 months after equecabtagene autoleucel treatment |
| Time to Response， TTR | up to 24 weeks | From the time the patient received equecabtagene autoleucel to the first recorded remission of the disease |
| Time to Complete Response， TTCR | up to 24 weeks | From the time the patient received equecabtagene autoleucel to the first recorded complete remission of the disease (time interval between CR or sCR) |
| Adverse Event， AE | up to 24 weeks | After the patient received treatment with equecabtagene autoleucel, the investigators considered all adverse events and serious adverse events (SAE) related to the treatment with Equecabtagene Autoleucel. |
Countries
China
Contacts
Primary ContactYang Liu, Doctor
Backup ContactJin Lu
Outcome results
None listed